Vir ( VIR ) Q2 Revenue Drops 61%
Vir Biotechnology ( NASDAQ:VIR ) , a clinical-stage biotech focused on infectious diseases and immuno-oncology, reported results on August 6, 2025. The company announced a net loss per share of $ ( 0.80 ) ( GAAP ) . Revenue ( GAAP ) also fell short, reaching only $1.2 million against estimates of ...
Vir Biotechnology, Inc. ( VIR ) Reports Q2 Loss, Lags Revenue Estimates
Vir Biotechnology (VIR) delivered earnings and revenue surprises of -11.11% and -84.12%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
GSK Beats on Q2 Earnings & Sales, Stock Gains on '25 Outlook Raise
GSK's Q2 earnings and revenues top forecasts, with Specialty Medicines and Vaccines driving growth and a raised 2025 outlook boosting shares.
Vir Biotechnology, Inc. ( VIR ) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Vir Biotechnology (VIR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vir Biotechnology ( VIR ) Soars 11.9%: Is Further Upside Left in the Stock?
Vir Biotechnology (VIR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
BlueSphere Bio Appoints Alan Korman, Ph.D. as Chief Scientific Officer
PITTSBURGH, May 16, 2025 ( GLOBE NEWSWIRE ) -- BlueSphere Bio, a clinical stage drug development company focused on novel T cell based therapies, today announced the appointment of Alan Korman, Ph.D., as Chief Scientific Officer.
Marriott International To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Monday - Medicus Pharma ( NASDAQ:MDCX ) , Marriott International ( NASDAQ:MAR )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Guggenheim cut Intellia Therapeutics, Inc. NTLA price target from $55 to $45.
Vir Biotechnology, Inc. ( VIR ) Reports Q1 Loss, Lags Revenue Estimates
Vir Biotechnology (VIR) delivered earnings and revenue surprises of -6.02% and 84.51%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025 - Atea Pharmaceuticals ( NASDAQ:AVIR )
Panel to Discuss Current Challenges Encountered by Patients with HCV, Results from Atea's Phase 2 Study of the Regimen of Bemnifosbuvir and Ruzasvir, and What a New Optimized HCV Therapy Could Provide for Prescribers and Patients Event to Replace Atea's First Quarter 2025 Earnings Conference Call.
GSK Q1 Earnings Beat, Sales Lag, Stock Gains on Tariff Reassurance
GSK reports mixed first-quarter 2025 results. Shares rise in pre-market after it reaffirms guidance and says it is "well positioned" to handle the U.S. tariffs.
Vir Biotechnology, Inc. ( VIR ) Reports Q4 Loss, Lags Revenue Estimates
Vir Biotechnology (VIR) delivered earnings and revenue surprises of 10.59% and 15.22%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
GSK Beats on Q4 Earnings & Sales, Stock Up on Raised Long-Term Outlook
GSK reports better-than-expected Q4 earnings. It also announces a new share buyback program and raises the long-term sales outlook for 2031 by $2 billion.
NGM Bio Announces Appointment of Wendy Yeh, M.D. as Chief Medical Officer
Dr. Yeh will oversee the continued clinical development of NGM Bio's key programs, NGM120 for hyperemesis gravidarum and cancer cachexia, and aldafermin for primary sclerosing cholangitis
Morgan Stanley Doubles Vir Biotechnology Price Forecast - Here's Why - Vir Biotechnology ( NASDAQ:VIR )
50% of patients receiving VIR-5818 doses ≥400 µg/kg showed tumor shrinkage. Morgan Stanley upgrades Vir Biotechnology to Overweight with a $20 price target. On Wednesday, Vir Biotechnology, Inc.
Biotech Stock Roundup: NMRA Plunges on Study Failure, HOTH, VIR Soar on Study Data & More
NMRA and HOTH are in the spotlight in the biotech sector on study data announcement.
VIR Stock Up on Early Safety & Efficacy Data on Two Cancer Candidates
Vir Biotechnology posts encouraging initial data from phase I studies evaluating VIR-5818 and VIR-5500 in heavily pretreated patients with various solid tumors.
Vir Biotechnology Stock Soars On Prostate Cancer Trial Data - Here's Why - Vir Biotechnology ( NASDAQ:VIR )
On Wednesday, Vir Biotechnology, Inc. VIR stock traded higher after the company presented initial Phase 1 data from two of its dual-masked T-cell engagers ( TCEs ) : VIR-5818, which targets a variety of HER2-expressing solid tumors, and VIR-5500, which targets PSMA in metastatic ...
AAR Posts Upbeat Results, Joins AngioDynamics, eBay, Cal-Maine Foods And Other Big Stocks Moving Higher On Wednesday - Adtran Holdings ( NASDAQ:ADTN ) , Absci ( NASDAQ:ABSI )
U.S. stocks were lower, with the Dow Jones index falling over 150 points on Wednesday. Shares of AAR Corp. AIR rose sharply during Tuesday's session after posted stronger-than-expected second-quarter results. The company reported quarterly earnings of 90 cents per share, which beat the analyst ...
JANX Stock Hits Record High on Prostate Cancer Study Data
An early-stage study data shows that treatment with Janux's JANX007 generates deep and durable efficacy responses in heavily pretreated patients with mCRPC.
Why Credo Technology Group Shares Are Trading Higher By 40%; Here Are 20 Stocks Moving Premarket - Credo Technology Group ( NASDAQ:CRDO ) , Aptorum Gr ( NASDAQ:APM )
Shares of Credo Technology Group Holding Ltd CRDO rose sharply in today's pre-market trading after the company reported better-than-expected second-quarter financial results issued guidance that was above estimates. Credo Technology Group shares jumped 40.2% to $67.00 in the pre-market trading ...
What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday? - Vir Biotechnology ( NASDAQ:VIR )
On Friday, Vir Biotechnology, Inc. VIR announced end-of-treatment data from Part B of the MARCH Phase 2 study evaluating combinations of tobevibart and elebsiran, with or without pegylated interferon alfa ( PEG-IFNα ) , in participants with chronic hepatitis B.
Vir Biotechnology, Inc. ( VIR ) Reports Q3 Loss, Lags Revenue Estimates
Vir Biotechnology (VIR) delivered earnings and revenue surprises of -62.50% and 72.54%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
GSK Q3 Earnings Top, Stock Down on Lowered '24 View for Vaccine Sales
GSK's Q3 earnings beat estimates but sales miss the same. The company also lowers its outlook for vaccine sales for the rest of the year due to weak U.S. demand.
Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031 - Inovio Pharmaceuticals ( NASDAQ:INO ) , Moderna ( NASDAQ:MRNA )
PALM BEACH, Fla., Sept. 04, 2024 ( GLOBE NEWSWIRE ) -- FN Media Group News Commentary - The emergence of SARS-CoV-2, which triggered the COVID-19 pandemic with overall is widely regarded as the greatest medical emergency of the twentieth century. COVID-19's impact on global society would be felt ...
Engrail Therapeutics Appoints Paul Cayer as Chief Financial Officer and Saira Ramasastry to Board of Directors
SAN DIEGO, Aug. 08, 2024 ( GLOBE NEWSWIRE ) -- Engrail Therapeutics, a precision neuroscience company focused on the development of transformational therapies to improve the lives of patients, today announced the appointment of Paul Cayer as chief financial officer, and Saira Ramasastry to the ...
Wall Street Analysts See a 258.38% Upside in Vir Biotechnology ( VIR ) : Can the Stock Really Move This High?
The consensus price target hints at a 258.4% upside potential for Vir Biotechnology (VIR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Vir Biotechnology, Inc. ( VIR ) Reports Q2 Loss, Lags Revenue Estimates
Vir Biotechnology (VIR) delivered earnings and revenue surprises of -9.68% and 71.79%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
GSK Beats Q2 Earnings & Sales Estimates, Ups 2024 Guidance
GSK's revenues benefit from strong growth across the Specialty Medicines and General Medicines segments. It raises guidance for earnings and sales for the full year.
Brii Bio Presents New Data from Its Ongoing Phase 2 Chronic Hepatitis B Trials at EASL™ Congress 2024
New translational data demonstrate that BRII-179-induced immune responses are associated with high HBsAg reduction in a subset of participants with chronic HBV infection BRII-179 as add-on therapy induces functional antibody responses and contributes to improved sustained HBsAg loss in ...
Biotech Stock Roundup: GSK's Litigation Update, BIIB's Drug Approval & Other Updates
GSK and Biogen (BIIB) are in the spotlight following litigation updates and drug approval, respectively.
Vir Biotechnology ( VIR ) Up on Positive Data From HDV Study
Vir Biotechnology (VIR) rises on upbeat data from its phase II study evaluating tobevibart and elebsiran for the treatment of people living with chronic hepatitis delta.
Why Is Infectious Disease-Focused Vir Biotechnology Stock Trading Higher On Wednesday? - Vir Biotechnology ( NASDAQ:VIR )
On Wednesday, Vir Biotechnology Inc VIR announced new preliminary data from its Phase 2 SOLSTICE hepatitis delta clinical trial evaluating tobevibart and elebsiran for chronic hepatitis delta. Preliminary data from the Phase 2 trial show that treatment with tobevibart alone or combined with ...
Ollie's Bargain Outlet Posts Upbeat Earnings, Joins Verint Systems, Guidewire Software And Other Big Stocks Moving Higher On Wednesday - Ollie's Bargain Outlet ( NASDAQ:OLLI )
U.S. stocks were mixed, with the Dow Jones index falling more than 100 points on Wednesday. Shares of Ollie's Bargain Outlet Holdings, Inc. OLLI rose sharply during Wednesday's session following better-than-expected first-quarter earnings.
Wall Street Analysts Think Vir Biotechnology ( VIR ) Could Surge 188.65%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 188.7% in Vir Biotechnology (VIR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Vir Biotechnology, Inc. ( VIR ) Reports Q1 Loss, Tops Revenue Estimates
Vir Biotechnology (VIR) delivered earnings and revenue surprises of 51.52% and 250.82%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
GSK Beats Q1 Earnings & Sales Estimates, Ups 2024 Guidance
GSK's revenues benefit from strong growth across the Specialty Medicines and Vaccines segments. The company raises guidance for earnings and sales for the full year.
What Makes Vir Biotechnology ( VIR ) a New Buy Stock
Vir Biotechnology (VIR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Carvana Posts Q4 Results, Joins LegalZoom.com, Comfort Systems And Other Big Stocks Moving Higher On Friday - Comfort Systems USA ( NYSE:FIX ) , Carvana ( NYSE:CVNA )
U.S. stocks were mostly higher, with the Dow Jones index gaining more than 100 points on Friday. Shares of Carvana Co. CVNA rose sharply during Friday's session after the company reported fourth-quarter financial results.
Wall Street Analysts Believe Vir Biotechnology, Inc. ( VIR ) Could Rally 186.41%: Here's is How to Trade
The consensus price target hints at an 186.4% upside potential for Vir Biotechnology, Inc. (VIR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Vir Biotechnology, Inc. ( VIR ) Reports Q4 Loss, Tops Revenue Estimates
Vir Biotechnology, Inc. (VIR) delivered earnings and revenue surprises of 24.56% and 31.69%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
GSK Lags Q4 Earnings, Tops Sales, Issues Upbeat '24 Guidance
GSK's revenues benefit from strong growth across all segments, especially the Shingles and RSV vaccines. The company also issues fresh 2024 guidance for all its segments.
Vir Biotechnology ( VIR ) Gains 21.7% in 3 Months: Here's Why
After a major pipeline setback, Vir Biotechnology (VIR) stock gains 21.7% in three months on its restructuring plan to cut operating expenses.
Regeneron ( REGN ) Surges 3.0%: Is This an Indication of Further Gains?
Regeneron (REGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
It's Small Stocks' Time To Rally - Analysts Like These 11 Best
It's been all about the biggest of the big S&P 500 stocks all year. But now, investors are starting to look for big gains from small stocks.
Brii Bio Presents New Data Highlighting Progress Towards Achieving HBV Functional Cure at AASLD's The Liver Meeting® 2023
Brii Bio Presents New Data Highlighting Progress Towards Achieving HBV Functional Cure at AASLD's The Liver ... PR ...
Softbank Vision Funds lose $3.86 billion in investments in H1
Japanese investor SoftBank Group Corp's tech-focused Vision funds reported an investment loss of 583.3 billion yen or $3.86 billion for the first half of this fiscal year. This loss was attributed to the weak performance and lower valuations of some of its bets, including a slump in shares of ...
GSK Beats on Q3 Earnings and Sales, Raises 2023 Guidance
GSK's revenues benefit from strong growth across the Specialty Medicines and Vaccines segments. The company raises guidance for earnings and sales on the back of strong RSV vaccine sales.
Dropbox handing over 25% of San Francisco HQ back to landlord as commercial real estate softens
San Francisco is seeing its highest office vacancy rate since at least 2007 as Dropbox and other companies allow employees to work from home ...
HHS awards over $500 million to advance vaccines, therapeutics - .com
HHS awards over $500 million to advance vaccines, therapeutics UPI News ...
Vir Biotechnology to Participate in the H.C. Wainwright 4th Annual Hepatitis B Virus ( HBV ) Conference
Vir Biotechnology is participating in the H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Conference on Wednesday, October ...
